TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xspray Pharma AB ( (SE:XSPRAY) ) has provided an update.
Xspray Pharma AB announced that its rights issue was oversubscribed, leading to an increase and full utilization of the over-allotment issue, raising approximately SEK 161 million before transaction costs. This financial boost is set to strengthen Xspray’s market position, enabling the launch of Dasynoc® upon FDA approval and accelerating development of other products, thereby enhancing its project portfolio and financial resilience.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in developing improved versions of already approved drugs, focusing on oncology treatments. The company leverages its proprietary HyNap technology to enhance drug formulations, aiming to improve patient outcomes and expand market opportunities.
Average Trading Volume: 54,153
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.98B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.